We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$7K
Cap. Flow
-$8.9M
Cap. Flow %
-7.79%
Top 10 Hldgs %
52.99%
Holding
94
New
29
Increased
16
Reduced
28
Closed
16

Top Buys

Rank Stock Value
1
SYT
Syngenta Ag
SYT
+$5.86M
2
BFYT
Benefytt Technologies, Inc. Class A Common Stock
BFYT
+$5.08M
3
SHOR
ShoreTel, Inc.
SHOR
+$2.1M
4
SANW
S&W Seed Co
SANW
+$1.65M
5
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$1.38M

Top Sells

Rank Stock Value
1
CALX icon
Calix
CALX
+$6.16M
2
DRRX
DURECT Corp
DRRX
+$3.14M
3
LSAK icon
Lesaka Technologies
LSAK
+$3.03M
4
ARAY icon
Accuray
ARAY
+$2.56M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 46.71%
2 Technology 20.22%
3 Communication Services 8.22%
4 Materials 7.79%
5 Financials 5.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MMAT
76
DELISTED
Meta Materials Inc. Common Stock
MMAT
$74K 0.06%
+73
New +$70.5K
OME
77
DELISTED
Omega Protein
OME
$45K 0.04%
+3,700
New +$42.4K
LMNR icon
78
Limoneira
LMNR
$246M
$39K 0.03%
1,700
-10,192
-86% -$230K
CALX icon
79
Calix
CALX
$2.37B
– –
-639,165
Closed -$6.16M
CAPL icon
80
CrossAmerica Partners
CAPL
$888M
– –
-5,500
Closed -$157K
DRRX
81
DELISTED
DURECT Corp
DRRX
– –
-181,397
Closed -$3.14M
EPD icon
82
Enterprise Products Partners
EPD
$84.3B
– –
-1,200
Closed -$40K
ICAD
83
DELISTED
iCAD Inc
ICAD
– –
-50,510
Closed -$590K
ITRI icon
84
Itron
ITRI
$4.35B
– –
-5,800
Closed -$240K
LSTA icon
85
Lisata Therapeutics
LSTA
$16.4M
– –
-941
Closed -$963K
SBS icon
86
Sabesp
SBS
$17B
– –
-39,190
Closed -$86K
SRPT icon
87
Sarepta Therapeutics
SRPT
$2.28B
– –
-16,900
Closed -$345K
TPH
88
DELISTED
Tri Pointe Homes
TPH
– –
-6,700
Closed -$134K
VSTM icon
89
Verastem
VSTM
$668M
– –
-9,252
Closed -$1.27M
DMK
90
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-600
Closed -$267K
ACER
91
DELISTED
Acer Therapeutics Inc
ACER
– –
-2,400
Closed -$366K
SRNE
92
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-38,900
Closed -$316K
TWTR
93
DELISTED
Twitter, Inc.
TWTR
– –
-13,400
Closed -$852K
ONCY
94
DELISTED
ONCOLYTICS BIOTECH INC
ONCY
– –
-222,900
Closed -$345K
1 2 3
4

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Sophrosyne Capital held 94 positions worth $114M, up 0.01% from $114M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sophrosyne Capital withdrew a net $8.9M in Q1 2014, closing 16 positions and reducing 28 holdings. Its most notable exit was Calix, an estimated $6.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 55% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sophrosyne Capital opened a new position in Benefytt Technologies, Inc. Class A Common Stock worth $4.65M.

  • Sophrosyne Capital's largest Q1 2014 buy was Benefytt Technologies, Inc. Class A Common Stock: 449,845 shares worth $4.65M.
  • Sophrosyne Capital added most to Syngenta Ag in Q1 2014, an estimated $5.86M increase.
  • Sophrosyne Capital's biggest Q1 2014 reduction was Lesaka Technologies, cutting an estimated $3.03M.
  • Sophrosyne Capital fully exited Calix in Q1 2014, selling an estimated $6.16M.
  • Sophrosyne Capital's ten largest holdings make up 53% of its $114M portfolio in Q1 2014.
  • Sophrosyne Capital opened 29 new positions and closed 16 in Q1 2014.
  • Sophrosyne Capital's portfolio value rose 0.01% quarter-over-quarter to $114M.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.